Kunchok Dorjee1, Hyunju Kim2, Elizabeth Bonomo1, Rinchen Dolma3. 1. School of Medicine Division of Infectious Diseases, Center for TB Research, Johns Hopkins University, Baltimore, Maryland, United States of America. 2. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America. 3. Center for Alcohol and Addiction Studies, Brown University School of Public Health, Brown University, Providence, Rhode Island, United States of America.
Abstract
INTRODUCTION: Progression of COVID-19 to severe disease and death is insufficiently understood. OBJECTIVE: Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19 patients who were hospitalized. METHODS: We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore's adjusted confidence intervals to address heterogeneity. RESULTS: Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18-23%); 23% (19-27%) in the US and Europe and 11% (7-16%) for China. Of those that died, 85% were aged≥60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46-60) for heart disease, 51% (43-59) for COPD, 48% (37-63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23-36%) for hypertension, and 24% (17-33%) for diabetes. Summary relative risk (sRR) of death were higher for age≥60 years [sRR = 3.6; 95% CI: 3.0-4.4], males [1.3; 1.2-1.4], smoking history [1.3; 1.1-1.6], COPD [1.7; 1.4-2.0], hypertension [1.8; 1.6-2.0], diabetes [1.5; 1.4-1.7], heart disease [2.1; 1.8-2.4], CKD [2.5; 2.1-3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities. CONCLUSIONS: Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.
INTRODUCTION: Progression of COVID-19 to severe disease and death is insufficiently understood. OBJECTIVE: Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19patients who were hospitalized. METHODS: We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore's adjusted confidence intervals to address heterogeneity. RESULTS: Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18-23%); 23% (19-27%) in the US and Europe and 11% (7-16%) for China. Of those that died, 85% were aged≥60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46-60) for heart disease, 51% (43-59) for COPD, 48% (37-63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23-36%) for hypertension, and 24% (17-33%) for diabetes. Summary relative risk (sRR) of death were higher for age≥60 years [sRR = 3.6; 95% CI: 3.0-4.4], males [1.3; 1.2-1.4], smoking history [1.3; 1.1-1.6], COPD [1.7; 1.4-2.0], hypertension [1.8; 1.6-2.0], diabetes [1.5; 1.4-1.7], heart disease [2.1; 1.8-2.4], CKD [2.5; 2.1-3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities. CONCLUSIONS: Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.
Authors: Jeffrey D Sachs; Salim S Abdool Karim; Lara Aknin; Joseph Allen; Kirsten Brosbøl; Francesca Colombo; Gabriela Cuevas Barron; María Fernanda Espinosa; Vitor Gaspar; Alejandro Gaviria; Andy Haines; Peter J Hotez; Phoebe Koundouri; Felipe Larraín Bascuñán; Jong-Koo Lee; Muhammad Ali Pate; Gabriela Ramos; K Srinath Reddy; Ismail Serageldin; John Thwaites; Vaira Vike-Freiberga; Chen Wang; Miriam Khamadi Were; Lan Xue; Chandrika Bahadur; Maria Elena Bottazzi; Chris Bullen; George Laryea-Adjei; Yanis Ben Amor; Ozge Karadag; Guillaume Lafortune; Emma Torres; Lauren Barredo; Juliana G E Bartels; Neena Joshi; Margaret Hellard; Uyen Kim Huynh; Shweta Khandelwal; Jeffrey V Lazarus; Susan Michie Journal: Lancet Date: 2022-09-14 Impact factor: 202.731
Authors: Matteo Bassetti; Daniele Roberto Giacobbe; Paolo Bruzzi; Emanuela Barisione; Stefano Centanni; Nadia Castaldo; Silvia Corcione; Francesco Giuseppe De Rosa; Fabiano Di Marco; Andrea Gori; Andrea Gramegna; Guido Granata; Angelo Gratarola; Alberto Enrico Maraolo; Malgorzata Mikulska; Andrea Lombardi; Federico Pea; Nicola Petrosillo; Dejan Radovanovic; Pierachille Santus; Alessio Signori; Emanuela Sozio; Elena Tagliabue; Carlo Tascini; Carlo Vancheri; Antonio Vena; Pierluigi Viale; Francesco Blasi Journal: Infect Dis Ther Date: 2021-07-30
Authors: Naheed Choudhry; Kate Drysdale; Carla Usai; Dean Leighton; Vinay Sonagara; Ruaridh Buchanan; Manreet Nijjar; Sherine Thomas; Mark Hopkins; Teresa Cutino-Moguel; Upkar S Gill; Graham R Foster; Patrick T Kennedy Journal: Front Med (Lausanne) Date: 2021-04-27
Authors: Snehal R Patel; Christiana Gjelaj; Rena Fletcher; Anne Luke; Alexandra Paschenko; Muhammad Farooq; Omar Saeed; Sasa Vukelic; Ulrich P Jorde Journal: Clin Transplant Date: 2021-05-03 Impact factor: 3.456
Authors: Jacob Burns; Ani Movsisyan; Jan M Stratil; Renke Lars Biallas; Michaela Coenen; Karl Mf Emmert-Fees; Karin Geffert; Sabine Hoffmann; Olaf Horstick; Michael Laxy; Carmen Klinger; Suzie Kratzer; Tim Litwin; Susan Norris; Lisa M Pfadenhauer; Peter von Philipsborn; Kerstin Sell; Julia Stadelmaier; Ben Verboom; Stephan Voss; Katharina Wabnitz; Eva Rehfuess Journal: Cochrane Database Syst Rev Date: 2021-03-25
Authors: Frank Trübner; Lisa Steigert; Fabian Echterdiek; Norma Jung; Kirsten Schmidt-Hellerau; Wolfram G Zoller; Julia-Stefanie Frick; You-Shan Feng; Gregor Paul Journal: PLoS One Date: 2021-07-21 Impact factor: 3.240